Target Symbol	Gene Abnormality	Citation(1)	Link(1)	Citation(2)	Link(2)	Citation(3)	Link(3)
ABL1/2	ABL1/2 gene fusions (BCR-ABL1, etc.)	Greuber, E. K., Smith-Pearson, P., Wang, J., & Pendergast, A. M. (2013). Role of ABL family kinases in cancer: From leukaemia to solid tumours. Nature Reviews Cancer, 13(8), 559-571. doi:10.1038/nrc3563	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935732/				
ACVR1	ACVR1	Taylor, K. R., Vinci, M., Bullock, A. N., & Jones, C. (2014). ACVR1 mutations in DIPG: lessons learned from FOP. Cancer Research, 74(17), 4565–4570. http://doi.org/10.1158/0008-5472.CAN-14-1298	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154859/				
ALK	ALK and ALK gene fusions	Holla, V. R., Elamin, Y. Y., Bailey, A. M., Johnson, A. M., Litzenburger, B. C., Khotskaya, Y. B., … Simon, G. R. (2017). ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harbor Molecular Case Studies, 3(1), a001115. http://doi.org/10.1101/mcs.a001115	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171696/				
BRAF	BRAF	Kieran, M. W. (2014). Targeting BRAF in Pediatric Brain Tumors. American Society of Clinical Oncology Educational Book, 34. doi:10.14694/edbook_am.2014.34.e436	https://meetinglibrary.asco.org/record/89039/edbook#fulltext	Dahiya S, Emnett RJ, Haydon DH, et al. BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol. 2014;16:318-319.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895374/		
CDK12	EWSR1-FLI1	Iniguez, A. B., Stolte, B., Wang, E. J., Conway, A. S., Alexe, G., Dharia, N. V., . . . Stegmaier, K. (2018). EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell, 33(2). doi:10.1016/j.ccell.2017.12.009	https://www.ncbi.nlm.nih.gov/pubmed/29358035				
CSF1R	CSF1R gene fusions	Rovida, E., & Sbarba, P. D. (2015). Colony-Stimulating Factor-1 Receptor in the Polarization of Macrophages: A Target for Turning Bad to Good Ones? Journal of Clinical & Cellular Immunology, 06(06). doi:10.4172/2155-9899.1000379	https://www.omicsonline.org/open-access/colonystimulating-factor1-receptor-in-the-polarization-of-macrophagesa-target-for-turning-bad-to-good-ones-2155-9899-1000379.pdf	Butowski, N., Colman, H., Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., . . . Prados, M. (2015). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology, 18(4), 557-564. doi:10.1093/neuonc/nov245	https://academic.oup.com/neuro-oncology/article/18/4/557/2509330		
CTNNB1 (β-catenin)	CTNNB1	Shukla, N., Ameur, N., Yilmaz, I., Nafa, K., Lau, C., Marchetti, A., . . . Ladanyi, M. (2011). Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways. Clinical Cancer Research, 18(3), 748-757. doi:10.1158/1078-0432.ccr-11-2056	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271129/				
DDX3X	DDX3X	Epling, L. B., Grace, C. R., Lowe, B. R., Partridge, J. F., & Enemark, E. J. (2015). Cancer-associated mutants of RNA helicase DDX3X are defective in RNA-stimulated ATP hydrolysis. Journal of Molecular Biology, 427(9), 1779–1796. http://doi.org/10.1016/j.jmb.2015.02.015	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402148/				
DOT1L	MLL gene fusions	Wong, M., Tee, A., Milazzo, G., Bell, J., Hüttelmaier, S., Polly, P., . . . Liu, T. (2017). Abstract LB-080: The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription. Cancer Research, 77(13 Supplement). doi:10.1158/1538-7445.am2017-lb-080	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633909/				
ERK	BRAF, MAP2K1	Tp, T. A. (2015). Targeted Therapy for MAPK Alterations in Pediatric Gliomas. Brain Disorders & Therapy, S2. doi:10.4172/2168-975x.s2-005	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627711/	Knight, T., & Irving, J. A. (2014). Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. Frontiers in Oncology, 4. doi:10.3389/fonc.2014.00160	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067595/		
EWSR1-FLI1	EWSR1-FLI1	Gamberi, G., Cocchi, S., Benini, S., Magagnoli, G., Morandi, L., Kreshak, J., . . . Alberghini, M. (2011). Molecular Diagnosis in Ewing Family Tumors. The Journal of Molecular Diagnostics, 13(3), 313-324. doi:10.1016/j.jmoldx.2011.01.004	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077725/				
EZH2	SMARCB1, SMARCA4	D'Angelo, V., Iannotta, A., Ramaglia, M., Lombardi, A., Zarone, M. R., Desiderio, V., . . . Caraglia, M. (2015). EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches. Journal of Experimental & Clinical Cancer Research, 34(1). doi:10.1186/s13046-015-0191-0	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535295/	Chang, C., & Hung, M. (2011). The role of EZH2 in tumour progression. British Journal of Cancer, 106(2), 243-247. doi:10.1038/bjc.2011.551	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132442/		
FGFR	FGFR and FGFR gene fusions	Venneti, S., & Huse, J. T. (2015). The Evolving Molecular Genetics of Low-grade Glioma. Advances In Anatomic Pathology, 22(2), 94-101. doi:10.1097/pap.0000000000000049	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667550/	Porta, R., Borea, R., Coelho, A., Khan, S., Araújo, A., Reclusa, P., . . . Rolfo, C. (2017). FGFR a promising druggable target in cancer: Molecular biology and new drugs. Critical Reviews in Oncology/Hematology, 113, 256-267. doi:10.1016/j.critrevonc.2017.02.018	http://www.croh-online.com/article/S1040-8428(17)30085-9/fulltext	Linzey, J. R., Marini, B., Mcfadden, K., Lorenzana, A., Mody, R., Robertson, P. L., & Koschmann, C. (2017). Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma". Npj Precision Oncology, 1(1). doi:10.1038/s41698-017-0036-8	https://www.nature.com/articles/s41698-017-0036-8
FLT3	FLK2, STK1, CD135	Grafone, T., Palmisano, M., Nicci, C., & Storti, S. (2012). An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: Biology and treatment. Oncology Reviews, 6(1), 8. doi:10.4081/oncol.2012.e8	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419636/	Levis, M. (2013). FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2013, 220–226. http://doi.org/10.1182/asheducation-2013.1.220	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714709/		
Gamma secretase	NOTCH1 and FBXW7	Kolb, E. A., Gorlick, R., Keir, S. T., Maris, J. M., Lock, R., Carol, H., . . . Smith, M. A. (2011). Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatric Blood & Cancer, 58(5), 815-818. doi:10.1002/pbc.23290	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276746/				
Histone 3 G34R/V	Histone 3 G34R/V	Yuen, B., & Knoepfler, P. (2013). Histone H3.3 Mutations: A Variant Path to Cancer. Cancer Cell, 24(5), 567-574. doi:10.1016/j.ccr.2013.09.015	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882088/				
Histone 3 K27M	Histone 3 K27M	Yuen, B., & Knoepfler, P. (2013). Histone H3.3 Mutations: A Variant Path to Cancer. Cancer Cell, 24(5), 567-574. doi:10.1016/j.ccr.2013.09.015	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882088/				
IDH1 and IHD2	IDH1 and IDH2	Yang, H., Ye, D., Guan, K., & Xiong, Y. (2012). IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. Clinical Cancer Research, 18(20), 5562-5571. doi:10.1158/1078-0432.ccr-12-1773	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897211/				
JAK1, 2, and 3	JAK1, 2, and 3	Yang, H., Ye, D., Guan, K., & Xiong, Y. (2012). IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. Clinical Cancer Research, 18(20), 5562-5571. doi:10.1158/1078-0432.ccr-12-1773	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897211/				

MDM2	MDM2, TP53	Barone, G., Tweddle, D., Shohet, J., Chesler, L., Moreno, L., Pearson, A., & Maerken, T. (2014). MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Current Drug Targets, 15(1), 114-123. doi:10.2174/13894501113149990194	https://www.ncbi.nlm.nih.gov/pubmed/24387312	Goethem, A. V., Yigit, N., Moreno-Smith, M., Vasudevan, S. A., Barbieri, E., Speleman, F., . . . Maerken, T. V. (2017). Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma. Oncotarget, 8(34). doi:10.18632/oncotarget.18982	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593624/
MEK	BRAF and BRAF gene fusions, MAP2K1, NF1	Ciccarelli, C., Vulcano, F., Milazzo, L., Gravina, G. L., Marampon, F., Macioce, G., . . . Zani, B. M. (2016). Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population. Molecular Cancer, 15(1). doi:10.1186/s12943-016-0501-y	https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-016-0501-y		
Menin	MLL gene fusions	Slany, R. K. (2016). The molecular mechanics of mixed lineage leukemia. Oncogene, 35(40), 5215-5223. doi:10.1038/onc.2016.30	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704309/		
MET	MET	Bouffet, E. (2007). Faculty of 1000 evaluation for Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Childrens Oncology Group. F1000 - Post-publication Peer Review of the Biomedical Literature. doi:10.3410/f.1098180.554184	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123765/		
MLL	MLL gene fusions	Winters, A. C., & Bernt, K. M. (2017). MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches. Frontiers in Pediatrics, 5. doi:10.3389/fped.2017.00004	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299633/		
mTOR	TSC1, TSC2	Barrett, D., Brown, V. I., Grupp, S. A., & Teachey, D. T. (2012). Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies. Pediatric Drugs, 14(5), 299-316. doi:10.1007/bf03262236	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214862/		
MYC	MYC translocations and amplification	Hutter, S., Bolin, S., Weishaupt, H., & Swartling, F. (2017). Modeling and Targeting MYC Genes in Childhood Brain Tumors. Genes, 8(4), 107. doi:10.3390/genes8040107	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406854/		
MYCN	MYCN amplification	Sala, A. (2015). Editorial: Targeting MYCN in Pediatric Cancers. Frontiers in Oncology, 4. doi:10.3389/fonc.2014.00330	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429566/		
Neoantigens	MSH2, MLH1, MSH6, PMS2 POLE, and POLD1	Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69-74. doi:10.1126/science.aaa4971	http://science.sciencemag.org/content/348/6230/69/tab-pdf		
NFkappaB	RELA fusion	Cahill, K. E., Morshed, R. A., & Yamini, B. (2015). Nuclear factor-κB in glioblastoma: Insights into regulators and targeted therapy. Neuro-Oncology, 18(3), 329-339. doi:10.1093/neuonc/nov265	https://academic.oup.com/neuro-oncology/article/18/3/329/2509337		
NOTCH1	NOTCH1, FBXW7	Zage, P. E., Nolo, R., Fang, W., Stewart, J., Garcia-Manero, G., & Zweidler-Mckay, P. A. (2011). Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatric Blood & Cancer, 58(5), 682-689. doi:10.1002/pbc.23202	https://www.ncbi.nlm.nih.gov/pubmed/21744479	Ferrando, A. A. (2009). The role of NOTCH1 signaling in T-ALL. Hematology, 2009(1), 353-361. doi:10.1182/asheducation-2009.1.353	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847371/
NT5C2	NT5C2	Meyer, J. A., Wang, J., Hogan, L. E., Yang, J. J., Dandekar, S., Patel, J. P., … Carroll, W. L. (2013). Relapse specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nature Genetics, 45(3), 290–294. http://doi.org/10.1038/ng.2558	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681285/		
NTRK	NTRK gene fusions	Prasad, M. L., Vyas, M., Horne, M. J., Virk, R. K., Morotti, R., Liu, Z., . . . Nikiforov, Y. E. (2016). NTRKfusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer, 122(7), 1097-1107. doi:10.1002/cncr.29887	https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.29887		
PAX-FOXO1	PAX-FOXO1	Linardic, C. M. (2008). PAX3–FOXO1 fusion gene in rhabdomyosarcoma. Cancer Letters, 270(1), 10-18. doi:10.1016/j.canlet.2008.03.035	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575376/		
PDGFRA/B	PDGFRA/B gene fusions	Heldin, C. (2013). Targeting the PDGF signaling pathway in tumor treatment. Cell Communication and Signaling, 11(1), 97. doi:10.1186/1478-811x-11-97	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878225/		
PI3Kα	PIK3CA	Khan, K. H., Yap, T. A., Yan, L., & Cunningham, D. (2013). Targeting the PI3K-AKT-mTOR signaling network in cancer. Chinese Journal of Cancer, 32(5), 253-265. doi:10.5732/cjc.013.10057	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845556/		
PPM1D (WIP1)	PPM1D (WIP1)	Milosevic, J., Eissler, N., Treis, D., Wicktröm, M., Fransson, S., Sveinbjornsson, B., . . . Kogner, P. (2017). Abstract 1945: PPM1D/Wip1, promising new target in childhood cancers neuroblastoma and medulloblastoma. Cancer Research, 77(13 Supplement), 1945-1945. doi:10.1158/1538-7445.am2017-1945	http://cancerres.aacrjournals.org/content/77/13_Supplement/1945		
RAS	RAS	Ward, A. F., Braun, B. S., & Shannon, K. M. (2012). Targeting oncogenic Ras signaling in hematologic malignancies. Blood, 120(17), 3397-3406. doi:10.1182/blood-2012-05-378596	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309527/		
RET	RET	Levy, A. S., Roth, M., Patterson, N., Scott, E., Quispe-Tintaya, W., Ewart, M. R., . . . Montagna, C. (2016). Abstract 15: Target next sequencing profiling of pediatric solid tumors: Potential use for the identification of actionable mutations. Clinical Cancer Research, 22(1 Supplement), 15-15. doi:10.1158/1557-3265.pmsclingen15-15	http://clincancerres.aacrjournals.org/content/22/1_Supplement/15	Dupain, C., Harttrampf, A. C., Urbinati, G., Geoerger, B., & Massaad-Massade, L. (2017). Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine. Molecular Therapy - Nucleic Acids, 6, 315-326. doi:10.1016/j.omtn.2017.01.005	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363511/
SHP2	SHP2	Liu, X., Zheng, H., Li, X., Wang, S., Meyerson, H. J., Yang, W., … Qu, C.-K. (2016). Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. Proceedings of the National Academy of Sciences of the United States of America, 113(4), 984–989. http://doi.org/10.1073/pnas.1508535113	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743778/		
Smoothened	PATCH1, SMO	Rimkus, T., Carpenter, R., Qasem, S., Chan, M., & Lo, H. (2016). Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers, 8(2), 22. doi:10.3390/cancers8020022	http://www.mdpi.com/2072-6694/8/2/22		
SYT-SSX	SYT-SSX	Stegmaier, S., Leuschner, I., Poremba, C., Ladenstein, R., Kazanowska, B., Ljungman, G., . . . Koscielniak, E. (2016). The prognostic impact of SYT-SSX fusion type and histological grade in pediatric patients with synovial sarcoma treated according to the CWS (Cooperative Weichteilsarkom Studie) trials. Pediatric Blood & Cancer, 64(1), 89-95. doi:10.1002/pbc.26206	https://www.ncbi.nlm.nih.gov/pubmed/27621063		

TP53	TP53	Rausch, T., Jones, D., Zapatka, M., Stütz, A., Zichner, T., Weischenfeldt, J., . . . Korbel, J. (2012). Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. Cell, 148(1-2), 59-71. doi:10.1016/j.cell.2011.12.013	https://www.nature.com/articles/nature25480

Target Symbol	Citation(1)	Link(1)	Citation(2)	Link(2)
AKR1C3	Liu, C., Hsu, Y., Pan, P., Wu, M., Ho, C., Su, L., . . . Christiani, D. C. (2008). Maternal and offspring genetic variants of AKR1C3 and the risk of childhood leukemia. Carcinogenesis, 29(5), 984-990. doi:10.1093/carcin/bgn071	http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.586.2963&rep=rep1&type=pdf		
BTK	Uckun, F., & D. (2013). Novel Bruton's tyrosine kinase inhibitors currently in development. OncoTargets and Therapy, 161. doi:10.2147/ott.s33732	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594038/		
CD7	Azad, V. F., Asl, A. A., Tashvighi, M., Mofrad, N. N., Haghighi, M., & Mehrvar, A. (2015). CD7 aberrant expression led to a lineage switch at relapsed childhood acute pre-B lymphoblastic leukemia. Medical Molecular Morphology, 49(1), 53-56. doi:10.1007/s00795-015-0117-0	https://www.ncbi.nlm.nih.gov/pubmed/26242204		
CD19	Shalabi, H., Angiolillo, A., & Fry, T. J. (2015). Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia. Frontiers in Pediatrics, 3, 80. http://doi.org/10.3389/fped.2015.00080	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589648/		
CD20	Dworzak, M. N., Schumich, A., Printz, D., Pötschger, U., Husak, Z., Attarbaschi, A., … Gadner, H. (2008). CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood, 112(10), 3982–3988. http://doi.org/10.1182/blood-2008-06-164129	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2581996/		
CD22	Sun, W., Gaynon, P. S., Sposto, R., & Wayne, A. S. (2015). Improving Access To Novel Agents For Childhood Leukemia. Cancer, 121(12), 1927–1936. http://doi.org/10.1002/cncr.29267	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457598/		
CD30	Nagpal, P., Akl, M. R., Ayoub, N. M., Tomiyama, T., Cousins, T., Tai, B., … Suh, K. S. (2016). Pediatric Hodgkin lymphoma– biomarkers, drugs, and clinical trials for translational science and medicine. Oncotarget, 7(41), 67551–67573. http://doi.org/10.18632/oncotarget.11509	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341896/		
CD33	O'Hear, C., Heiber, J. F., Schubert, I., Fey, G., & Geiger, T. L. (2015). Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. Haematologica, 100(3), 336–344. http://doi.org/10.3324/haematol.2014.112748	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349272/		
CD37	De Winde, C. M., Veenbergen, S., Young, K. H., Xu-Monette, Z. Y., Wang, X., Xia, Y., … van Spriel, A. B. (2016). Tetraspanin CD37 protects against the development of B cell lymphoma. The Journal of Clinical Investigation, 126(2), 653–666. http://doi.org/10.1172/JCI81041.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731177/		
CD38	Jiang, Z., Wu, D., Lin, S., & Li, P. (2016). CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia. Biomarker Research, 4, 23. http://doi.org/10.1186/s40364-016-0080-5	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159997/		
CD56	Aref, S., Azmy, E., El-Bakry, K., Ibrahim, L., & Mabed, M. (2017). Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients. Hematology, 1-8. doi:10.1080/10245332.2017.1404276	https://www.ncbi.nlm.nih.gov/pubmed/29144828	Neff, J., & Chen, D. (2017). Pediatric Philadelphia-positive B lymphoblastic leukemia with CD56 expression and L2 morphology: Case report and review of the literature. Human Pathology: Case Reports, 8, 9-12. doi:10.1016/j.ehpc.2016.12.002	https://www.sciencedirect.com/science/article/pii/S2214330016300803
CD70	Shaffer, D. R., Savoldo, B., Yi, Z., Chow, K. K. H., Kakarla, S., Spencer, D. M., … Gottschalk, S. (2011). T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood, 117(16), 4304–4314. http://doi.org/10.1182/blood-2010-04-278218	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087480/		
CD79b	Gordon, M. S., Kato, R. M., Lansigan, F., Thompson, A. A., Wall, R., & Rawlings, D. J. (2000). Aberrant B cell receptor signaling from B29 (Igβ, CD79b) gene mutations of chronic lymphocytic leukemia B cells. Proceedings of the National Academy of Sciences of the United States of America, 97(10), 5504–5509.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC25858/		
CD123/IL3RA	Testa, U., Pelosi, E., & Frankel, A. (2014). CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomarker Research, 2, 4. http://doi.org/10.1186/2050-7771-2-4	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928610/	Bonifant, C. L., Szoor, A., Torres, D., Joseph, N., Velasquez, M. P., Iwahori, K., … Gottschalk, S. (2016). CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Molecular Therapy, 24(9), 1615–1626. http://doi.org/10.1038/mt.2016.116.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113097/
CD276 (B7-H3)	Zhou, Z., Luther, N., Ibrahim, G. M., Hawkins, C., Vibhakar, R., Handler, M. H., & Souweidane, M. M. (2013). B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. Journal of Neuro-Oncology, 111(3), 257–264. http://doi.org/10.1007/s11060-012-1021-2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700828/		
DLL3	Zhao, X., Arca, D. D., Lim, W. K., Brahmachary, M., Carro, M. S., Ludwig, T., … Lasorella, A. (2009). The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. Developmental Cell, 17(2), 210–221. http://doi.org/10.1016/j.devcel.2009.07.009	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769073/		
EPHA2	Chow, K. K., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., … Gottschalk, S. (2013). T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma. Molecular Therapy, 21(3), 629–637. http://doi.org/10.1038/mt.2012.210	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589173/		
GD2	Capitini, C. M., Otto, M., DeSantes, K. B., & Sondel, P. M. (2014). Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncology (London, England), 10(9), 1659–1678. http://doi.org/10.2217/fon.14.62	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793725/		
GPC2	Bosse, K. R., Raman, P., Zhu, Z., Lane, M., Martinez, D., Heitzeneder, S., . . . Maris, J. M. (2017). Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell, 32(3). doi:10.1016/j.ccell.2017.08.003	http://www.cell.com/cancer-cell/abstract/S1535-6108(17)30346-X		
GPC3	Tanaka, S., Souzaki, R., Miyoshi, K., Kohashi, K., Oda, Y., Nakatsura, T., . . . Kinoshita, Y. (2014). Glypican 3 Expression in Pediatric Malignant Solid Tumors. European Journal of Pediatric Surgery, 25(01), 138-144. doi:10.1055/s-0034-1393961	https://www.ncbi.nlm.nih.gov/pubmed/25344940		
GPNMB	Roth, M., Barris, D. M., Piperdi, S., Kuo, V., Everts, S., Geller, D., . . . Gorlick, R. (2015). Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatric Blood & Cancer, 63(1), 32-38. doi:10.1002/pbc.25688	https://www.ncbi.nlm.nih.gov/pubmed/26305408		
ERBB2 (HER2/Neu)	Orentas, R. J., Lee, D. W., & Mackall, C. (2012). Immunotherapy Targets in Pediatric Cancer. Frontiers in Oncology, 2, 3. http://doi.org/10.3389/fonc.2012.00003	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355840/	Gilbertson, R. J. (2005). ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty. The Oncologist, 10(7), 508-517. doi:10.1634/theoncologist.10-7-508	http://theoncologist.alphamedpress.org/content/10/7/508.full
IL6	Egler, R. A., Burlingame, S. M., Nuchtern, J. G., & Russell, H. V. (2008). Interleukin-6 and soluble IL-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 14(21), 7028–7034. http://doi.org/10.1158/1078-0432.CCR-07-5017	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613275/		
IL13RA2	Deng, H., Zeng, J., Zhang, T., Gong, L., Zhang, H., Cheung, E., . . . Li, G. (2018). Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma. Molecular Cancer Research, 16(4), 623-633. doi:10.1158/1541-7786.mcr-17-0460	http://mcr.aacrjournals.org/content/molcanres/early/2018/02/16/1541-7786.MCR-17-0460.full.pdf		

LRRC15	Reynolds, P. A., Smolen, G. A., Palmer, R. E., Sgroi, D., Yajnik, V., Gerald, W. L., & Haber, D. A. (2003). Identification of a DNA-binding site and transcriptional target for the EWS–WT1(+KTS) oncoprotein. Genes & Development, 17(17), 2094–2107. http://doi.org/10.1101/gad.1110703	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC196452/
MAGE-A3	Jacobs, J. F., Brasseur, F., Kaa, C. A., Rakt, M. W., Figdor, C. G., Adema, G. J., . . . Vries, I. J. (2006). Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. International Journal of Cancer, 120(1), 67-74. doi:10.1002/ijc.22118	https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.22118
MSLN (mesothelin)	Steinbach, D. (2006). Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia. Clinical Cancer Research, 12(8), 2434-2441. doi:10.1158/1078-0432.ccr-05-2552	http://clincancerres.aacrjournals.org/content/clincanres/12/8/2434.full.pdf
NR5A1 (Steroidogenic factor-	Ferraz-de-Souza, B., Lin, L., & Achermann, J. C. (2011). Steroidogenic factor-1 (SF-1, NR5A1) and human disease. Molecular and Cellular Endocrinology, 336(1-2), 198–205. http://doi.org/10.1016/j.mce.2010.11.006	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057017/
NY-ESO-1	Singh, N., Kulikovskaya, I., Barrett, D. M., Binder-Scholl, G., Jakobsen, B., Martinez, D., … Grupp, S. A. (2016). T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. Oncoimmunology, 5(1), e1040216. http://doi.org/10.1080/2162402X.2015.1040216	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760344/
Olig2	Kupp, R., Shtayer, L., Tien, A.-C., Szeto, E., Sanai, N., Rowitch, D. H., & Mehta, S. (2016). Lineage-restricted OLIG2-RTK signaling governs the molecular subtype of glioma stem-like cells. Cell Reports, 16(11), 2838–2845. http://doi.org/10.1016/j.celrep.2016.08.040	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024710/
PIK3CD (PI3 kinase delta)	Khan, K. H., Yap, T. A., Yan, L., & Cunningham, D. (2013). Targeting the PI3K-AKT-mTOR signaling network in cancer. Chinese Journal of Cancer, 32(5), 253-265. doi:10.5732/cjc.013.10057	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633945/
PRAME	Oberthuer, A. (2004). The Tumor-Associated Antigen PRAME Is Universally Expressed in High-Stage Neuroblastoma and Associated with Poor Outcome. Clinical Cancer Research, 10(13), 4307-4313. doi:10.1158/1078-0432.ccr-03-0813	https://www.ncbi.nlm.nih.gov/pubmed/15240516
SYK	Cain, C. (2012). SYKing inhibitors on retinoblastoma. Science-Business EXchange, 5(7). doi:10.1038/scibx.2012.168	https://www.nature.com/scibx/journal/v5/n7/full/scibx.2012.168.html
WT1	Noronha, S. A., Farrar, J. E., Alonzo, T. A., Gerbing, R. B., Lacayo, N. J., Dahl, G. V., … Loeb, D. M. (2009). WT1 expression at diagnosis does not predict survival in pediatric AML: A report from the Children's Oncology Group. Pediatric Blood & Cancer, 53(6), 1136–1139. http://doi.org/10.1002/pbc.22142	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926132/

Target Symbol	Citation(1)	Link(1)	Citation(2)	Link(2)
CD40	Petrov I, Suntsova M, Mutorova O, et al. Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells. Aging (Albany NY). 2016;8(11):2936-2946. doi:10.18632/aging.101102.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5182073/	Vonderheide, R. H. (2007). Prospect of Targeting the CD40 Pathway for Cancer Therapy. Clinical Cancer Research, 13(4), 1083-1088. doi:10.1158/1078-0432.ccr-06-1893	http://clincancerres.aacrjournals.org/content/13/4/1083
CD47	An Anti-CD47 Antibody Is Effective in Pediatric Brain Tumor Models. (2017). Cancer Discovery, 7(5). doi:10.1158/2159-8290.cd-rw2017-057	http://cancerdiscovery.aacrjournals.org/content/7/5/453.2.full-text.pdf		
CD52	Angiolillo, A. L., Yu, A. L., Reaman, G., Ingle, A. M., Secola, R., & Adamson, P. C. (2009). A Phase II Study of Campath-1H in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Pediatric Blood & Cancer, 53(6), 978–983. http://doi.org/10.1002/pbc.22209	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120889/		
CXCR4	Matsuo, H., Nakamura, N., Tomizawa, D., Saito, A. M., Kiyokawa, N., Horibe, K., . . . Adachi, S. (2016). CXCR4Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatric Blood & Cancer, 63(8), 1394-1399. doi:10.1002/pbc.26035	https://www.ncbi.nlm.nih.gov/pubmed/27135782		
CTLA4	Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., … Mackall, C. L. (2016). Phase 1 Clinical Trial of Ipilimumab In Pediatric Patients With Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(6), 1364–1370. http://doi.org/10.1158/1078-0432.CCR-15-0491	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027962/		
GM-CSF	Aliper, A. M., Frieden-Korovkina, V. P., Buzdin, A., Roumiantsev, S. A., & Zhavoronkov, A. (2014). A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Medicine, 3(4), 737–746. http://doi.org/10.1002/cam4.239	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303143/		
IDO1	Folgiero, V., Goffredo, B. M., Filippini, P., Masetti, R., Bonanno, G., Caruso, R., . . . Rutella, S. (2013). Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget, 5(8). doi:10.18632/oncotarget.1504	https://preview.ncbi.nlm.nih.gov/pmc/articles/PMC4039144/		
IFN-gamma	Reid GSD, Shan X, Coughlin CM, et al. Interferon-gamma dependent infiltration of human T cells into neuroblastoma tumors in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(21):6602-6608. doi:10.1158/1078-0432.CCR-09-0829.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783677/		
IL-2	Capitini CM, Mackall CL, Wayne AS. Immune-based Therapeutics for Pediatric Cancer. Expert opinion on biological therapy. 2010;10(2):163-178. doi:10.1517/14712590903431022.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809805/		
LAG3	Birley, K., Chester, K., & Anderson, J. (2018). Antibody based therapy for childhood solid cancers. Current Opinion in Chemical Engineering, 19, 153-162. doi:10.1016/j.coche.2018.01.005	https://www.sciencedirect.com/science/article/pii/S2211339817300503		
OX40	Reuter, D., Staege, M. S., Kühnöl, C. D., & Föll, J. (2015). Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells. Frontiers in Oncology, 5, 242. http://doi.org/10.3389/fonc.2015.00242	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621427/		
PD-1/PD-L1	Chen, L., & Han, X. (2015). Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. The Journal of Clinical Investigation, 125(9), 3384–3391. http://doi.org/10.1172/JCI80011	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588282/		
RIG-I	Kaneda, Y. (2013). The RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis. Oncoimmunology, 2(4), e23566. http://doi.org/10.4161/onci.23566	https://www.ncbi.nlm.nih.gov/pubmed/23734313		
TIM3/TIM4	Williams, K. M., Grant, M., Ismail, M., Hoq, F., Martin-Manso, M., Hoover, J., . . . Bollard, C. (2017). Complete remissions post infusion of multiple tumor antigen specific T cells for the treatment of high risk leukemia and lymphoma patients after HCT. Cytotherapy, 19(5). doi:10.1016/j.jcyt.2017.03.013	https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.26772		
STING	Lemos, H., Mohamed, E., Huang, L., Ou, R., Pacholczyk, G., Arbab, A. S., … Mellor, A. L. (2016). STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Research, 76(8), 2076–2081. http://doi.org/10.1158/0008-5472.CAN-15-1456	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4873329/		

Target Symbol	Citation(1)	Link(1)	Citation(2)	Link(2)
AURKA (Aurora kinase A)	Wetmore C, Boyett J, Li S, et al. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. Neuro-Oncology. 2015;17(6):882-888. doi:10.1093/neuonc/nov017.	https://preview.ncbi.nlm.nih.gov/pmc/articles/PMC4483126/		
AURKB (Aurora kinase B)	Bavetsias, V., & Linardopoulos, S. (2015). Aurora Kinase Inhibitors: Current Status and Outlook. Frontiers in Oncology, 5, 278. http://doi.org/10.3389/fonc.2015.00278	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685048/		
AXL	Huey, M. G., Minson, K. A., Earp, H. S., DeRyckere, D., & Graham, D. K. (2016). Targeting the TAM Receptors in Leukemia. Cancers, 8(11), 101. http://doi.org/10.3390/cancers8110101	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126761/		
ATM	Takagi, M., Yoshida, M., Nemoto, Y., Tamaichi, H., Tsuchida, R., Seki, M., . . . Takita, J. (2017). Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. JNCI: Journal of the National Cancer Institute, 109(11). doi:10.1093/jnci/djx062	https://academic.oup.com/jnci/article/109/11/djx062/4096548		
ATR	Weber, A. M., & Ryan, A. J. (2015). ATM and ATR as therapeutic targets in cancer. Pharmacology & Therapeutics, 149, 124-138. doi:10.1016/j.pharmthera.2014.12.001	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066844/; [Erratum of the research article]https://www.sciencedirect.com/		
BCL2 family members (Bcl-2, Bcl-XL, Mcl-1, A1/BFL, BAK, BAX)	Chaber, R., Fiszer-Maliszewska, L., Noworolska-Sauren, D., Kwasnicka, J., Wrobel, G., & Chybicka, A. (2013). The BCL-2 Protein in Precursor B Acute Lymphoblastic Leukemia in Children. Journal of Pediatric Hematology/Oncology, 35(3), 180-187. doi:10.1097/mph.0b013e318286d29b	https://www.ncbi.nlm.nih.gov/pubmed/23511489		
BET bromodomain family	Wadhwa E, Nicolaides T (May 21, 2016) Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors. Cureus 8(5): e620. doi:10.7759/cureus.620	https://www.ncbi.nlm.nih.gov/pubmed/27382528	Hensel, T., Giorgi, C., Schmidt, O., Calzada-Wack, J., Neff, F., Buch, T., . . . Richter, G. H. (2015). Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Oncotarget, 7(2). doi:10.18632/oncotarget.6385	https://mediatum.ub.tum.de/doc/1398856/1398856.pdf
CDK4/6	Hamilton, E., & Infante, J. R. (2016). Targeting CDK4/6 in patients with cancer. Cancer Treatment Reviews, 45, 129-138. doi:10.1016/j.ctrv.2016.03.002	https://www.deepdyve.com/lp/elsevier/targeting-cdk4-6-in-patients-with-cancer-btnyBlik02		
CHK1	Prince, E. W., Balakrishnan, I., Shah, M., Mulcahy Levy, J. M., Griesinger, A. M., Alimova, I., … Vibhakar, R. (2016). Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. Oncotarget, 7(33), 53881–53894. http://doi.org/10.18632/oncotarget.10692	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288228/	Lowery, C. D., Vanwye, A. B., Dowless, M., Blosser, W., Falcon, B. L., Stewart, J., . . . Stancato, L. F. (2017). The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma. Clinical Cancer Research, 23(15), 4354-4363. doi:10.1158/1078-0432.ccr-16-2876	http://clincancerres.aacrjournals.org/content/early/2017/03/07/1078-0432.CCR-16-2876
CDK7	Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., … Gray, N. S. (2014). Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature, 511(7511), 616–620. http://doi.org/10.1038/nature13393	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244910/		
CDK9	Moreno, N., Holsten, T., Mertins, J., Zhogbi, A., Johann, P., Kool, M., … Kerl, K. (2017). Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors. Oncotarget, 8(49), 84986–84995. http://doi.org/10.18632/oncotarget.18583	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689588/		
CK2 (casein kinase 2)	Chua, M. M. J., Ortega, C. E., Sheikh, A., Lee, M., Abdul-Rassoul, H., Hartshorn, K. L., & Dominguez, I. (2017). CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals, 10(1), 18. http://doi.org/10.3390/ph10010018	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374422/	Buontempo, F., Mccubrey, J. A., Orsini, E., Ruzzene, M., Cappellini, A., Lonetti, A., . . . Martelli, A. M. (2017). Therapeutic targeting of CK2 in acute and chronic leukemias. Leukemia, 32(1), 1-10. doi:10.1038/leu.2017.301	https://www.nature.com/articles/leu2017301
DNA (alkylators)	Bobola, M. S. (2005). O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines. Clinical Cancer Research, 11(7), 2747-2755. doi:10.1158/1078-0432.ccr-04-2045	https://www.ncbi.nlm.nih.gov/pubmed/15814657		
DNA-PK	Dolman, M. E. M., van der Ploeg, I., Koster, J., Bate-Eya, L. T., Versteeg, R., Caron, H. N., & Molenaar, J. J. (2015). DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells. PLoS ONE, 10(12), e0145744. http://doi.org/10.1371/journal.pone.0145744	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696738/	Becher, O. J., Peterson, K. M., Khatua, S., Santi, M. R., & MacDonald, T. J. (2008). IGFBP2 is Overexpressed by Pediatric Malignant Astrocytomas and Induces the Repair Enzyme DNA-PK. Journal of Child Neurology, 23(10), 1205–1213. http://doi.org/10.1177/0883073808321766	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674842/
DNMT (DNA methyl transferase)	Diede, S. J., Guenthoer, J., Geng, L. N., Mahoney, S. E., Marotta, M., Olson, J. M., . . . Tapscott, S. J. (2009). DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. Proceedings of the National Academy of Sciences, 107(1), 234-239. doi:10.1073/pnas.0907606106	http://www.pnas.org/content/pnas/early/2009/11/30/0907606106.full.pdf		
FAK	Waters, A. M., Stafman, L. L., Garner, E. F., Mruthyunjayappa, S., Stewart, J. E., Mroczek-Musulman, E., & Beierle, E. A. (2016). Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells. Translational Oncology, 9(4), 263–273. http://doi.org/10.1016/j.tranon.2016.06.001	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925808/		
FOLR1 (folate receptor 1)	Orentas, R. J., Lee, D. W., & Mackall, C. (2012). Immunotherapy Targets in Pediatric Cancer. Frontiers in Oncology, 2, 3. http://doi.org/10.3389/fonc.2012.00003	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355840/		
GSK-3	Hu, Y., Gu, X., Li, R., Luo, Q., & Xu, Y. (2010). Glycogen synthase kinase-3β inhibition induces nuclear factor-κB-mediated apoptosis in pediatric acute lymphocyte leukemia cells. Journal of Experimental & Clinical Cancer Research : CR, 29(1), 154. http://doi.org/10.1186/1756-9966-29-154	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002327/	Mills, C. N., Nowsheen, S., Bonner, J. A., & Yang, E. S. (2011). Emerging Roles of Glycogen Synthase Kinase 3 in the Treatment of Brain Tumors. Frontiers in Molecular Neuroscience, 4, 47. http://doi.org/10.3389/fnmol.2011.00047	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223722/
HDAC	West, A. C., & Johnstone, R. W. (2014). New and emerging HDAC inhibitors for cancer treatment. The Journal of Clinical Investigation, 124(1), 30–39. http://doi.org/10.1172/JCI69738	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871231/		

HIF1A	Cruzeiro, G. A., Reis, M. B., Silveira, V. S., Lira, R. C., Jr, C. G., Neder, L., . . . Valera, E. T. (2018). HIF1A is Overexpressed in Medulloblastoma and its Inhibition Reduces Proliferation and Increases EPAS1 and ATG16L1 Methylation. Current Cancer Drug Targets, 18(3), 287-294. doi:10.2174/1568009617666170315162525	https://www.ncbi.nlm.nih.gov/m/pubmed/28302031/		
Hippo pathway (YAP, TAZ, TEADs)	Ahmed, A. A., Mohamed, A. D., Gener, M., Li, W., & Taboada, E. (2017). YAP and the Hippo pathway in pediatric cancer. Molecular & Cellular Oncology, 4(3), e1295127. http://doi.org/10.1080/23723556.2017.1295127	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462521/		
Hsp90	Li, W., Tsen, F., Sahu, D., Bhatia, A., Chen, M., Multhoff, G., & Woodley, D. T. (2013). Extracellular Hsp90 (eHsp90) as the Actual Target in Clinical Trials: Intentionally or Unintentionally. International Review of Cell and Molecular Biology, 303, 203–235. http://doi.org/10.1016/B978-0-12-407697-6.00005-2	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023563/		
IAPs (inhibitor-of-apoptosis)	Tyner, J. W., Jemal, A. M., Thayer, M., Druker, B. J., & Chang, B. H. (2012). Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia, 26(4), 623–632. http://doi.org/10.1038/leu.2011.249	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364442/		
LSD1	Theisen, E. R., Pishas, K. I., Saund, R. S., & Lessnick, S. L. (2016). Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting. Oncotarget, 7(14), 17616–17630. http://doi.org/10.18632/oncotarget.7124	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951237/		
MCT1 (monocarboxyate transporter 1)	Noble, R. A., Bell, N., Blair, H., Sikka, A., Thomas, H., Phillips, N., … Wedge, S. R. (2017). Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica, 102(7), 1247–1257. http://doi.org/10.3324/haematol.2016.163030	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566036/		
MGMT	Saletta, F., Wadham, C., Ziegler, D. S., Marshall, G. M., Haber, M., Mccowage, G., . . . Byrne, J. A. (2014). Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clinical, 1, 59-77. doi:10.1016/j.bbacli.2014.06.003	https://www.sciencedirect.com/science/article/pii/S2214647414000105		
NAMPT	Heske, C. M., Davis, M. I., Baumgart, J. T., Wilson, K., Gormally, M. V., Chen, L., . . . Thomas, C. J. (2017). Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clinical Cancer Research, 23(23), 7301-7311. doi:10.1158/1078-0432.ccr-17-1121	https://www.ncbi.nlm.nih.gov/pubmed/28899971		
NEDD8 activating enzyme (NAE)	Bhatia, S., Pavlick, A. C., Boasberg, P., Thompson, J. A., Mulligan, G., Pickard, M. D., … Hamid, O. (2016). A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. Investigational New Drugs, 34, 439–449. http://doi.org/10.1007/s10637-016-0348-5	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919369/	Mansouri, S., & Zadeh, G. (2015). Neddylation in glioblastomas. Neuro-Oncology, 17(10), 1305–1306. http://doi.org/10.1093/neuonc/nov165	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578592/
PARP	Ricks, T. K., Chiu, H.-J., Ison, G., Kim, G., McKee, A. E., Kluetz, P., & Pazdur, R. (2015). Successes and Challenges of PARP Inhibitors in Cancer Therapy. Frontiers in Oncology, 5, 222. http://doi.org/10.3389/fonc.2015.00222	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604313/		
PDK-1 (3-phosphoinositide-dependent protein kinase 1)	Velpula, K. K., Guda, M. R., Sahu, K., Tuszynski, J., Asuthkar, S., Bach, S. E., … Tsung, A. J. (2017). Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma. Oncotarget, 8(22), 35639–35655. http://doi.org/10.18632/oncotarget.16767	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482605/		
PIM1	Padi, S. K. R., Luevano, L. A., An, N., Pandey, R., Singh, N., Song, J. H., … Kraft, A. S. (2017). Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget, 8(18), 30199–30216. http://doi.org/10.18632/oncotarget.16320	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444737/		
PKA	Huang, S. Y., & Yang, J.-Y. (2015). Targeting the Hedgehog Pathway in Pediatric Medulloblastoma. Cancers, 7(4), 2110–2123. http://doi.org/10.3390/cancers7040880	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695880/		
PKC	Kikuchi, K., Soundararajan, A., Zarzabal, L. A., Weems, C. R., Nelon, L. D., Hampton, S. T., … Keller, C. (2013). Protein Kinase C iota as a Therapeutic Target in Alveolar Rhabdomyosarcoma. Oncogene, 32(3), 286–295. http://doi.org/10.1038/onc.2012.46	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360112/		
PLK1	Hartsink-Segers, S. A., Exalto, C., Clifford, S. C., Caron, H. N., Pieters, R., & Den Boer, M. L. (2012). Polo-Like Kinase 1 (PLK1) Inhibition Reduces Cell Proliferation and Induces Apoptosis in Childhood Acute Lymphoblastic Leukemia. Blood, 120(21), 3529. Accessed March 26, 2018. Retrieved from http://www.bloodjournal.org/content/120/21/3529.	http://www.bloodjournal.org/content/120/21/3529?sso-checked=true		
POL1	Jones, L., Carol, H., Evans, K., Richmond, J., Houghton, P. J., Smith, M. A., & Lock, R. B. (2016). A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia, 30(11), 2133-2141. doi:10.1038/leu.2016.192	https://www.nature.com/articles/leu2016192.pdf		
PRMT5	Jin, Y., Zhou, J., Xu, F., Jin, B., Cui, L., Wang, Y., … Pan, J. (2016). Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. The Journal of Clinical Investigation, 126(10), 3961–3980. http://doi.org/10.1172/JCI85239	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096815/		
Proteasome	Cloos, J., Roeten, M. S., Franke, N. E., Meerloo, J. V., Zweegman, S., Kaspers, G. J., & Jansen, G. (2017). (Immuno)proteasomes as therapeutic target in acute leukemia. Cancer and Metastasis Reviews, 36(4), 599-615. doi:10.1007/s10555-017-9699-4	https://www.ncbi.nlm.nih.gov/pubmed/29071527		

Survivin	Tyner, J. W., Jemal, A. M., Thayer, M., Druker, B. J., & Chang, B. H. (2012). Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia, 26(4), 623–632. http://doi.org/10.1038/leu.2011.249	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364442/
TGF-beta	Hahm, K. (1999). Correction: Repression of the gene encoding the TGF-β type II receptor is a major target of the EWS-FLI1 oncoprotein. Nature Genetics, 23(4), 481-481. doi:10.1038/70611	https://www.ncbi.nlm.nih.gov/pubmed/10508522
Thymidylate synthase	Rocha, J. C. C., Cheng, C., Liu, W., Kishi, S., Das, S., Cook, E. H., … Relling, M. V. (2005). Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 105(12), 4752–4758. http://doi.org/10.1182/blood-2004-11-4544	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895006/
Topoisomerase I/II	Bredel, C., Lassmann, S., Pollack, I., Knoth, R., Hamilton, R., Volk, B., . . . Bredel, M. (2005). DNA topoisomerase IIα and Her-2/neu gene dosages in pediatric malignant gliomas. International Journal of Oncology. doi:10.3892/ijo.26.5.1187	https://www.ncbi.nlm.nih.gov/pubmed/15809708
TRAIL	Kopp, L. M., & Katsanis, E. (2015). Targeted immunotherapy for pediatric solid tumors. OncoImmunology, 5(3). doi:10.1080/2162402x.2015.1087637	https://www.tandfonline.com/doi/full/10.1080/2162402X.2015.1087637
Tubulin	Stanton, R. A., Gernert, K. M., Nettles, J. H., & Aneja, R. (2011). Drugs That Target Dynamic Microtubules: A New Molecular Perspective. Medicinal Research Reviews, 31(3), 443–481. http://doi.org/10.1002/med.20242	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155728/
XPO1 (Exportin)	Etchin, J., Berezovskaya, A., Conway, A. S., Galinsky, I. A., Stone, R. M., Baloglu, E., … Look, A. T. (2017). KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia, 31(1), 143–150. http://doi.org/10.1038/leu.2016.145	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220128/
WEE1	Mueller, S., Hashizume, R., Yang, X., Kolkowitz, I., Olow, A. K., Phillips, J., … Haas-Kogan, D. A. (2014). Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro-Oncology, 16(3), 352–360. http://doi.org/10.1093/neuonc/not220	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922515/

Target Symbol	Citation(1)	Link(1)	Citation(2)	Link(2)
AR	Sun, J., Wang, D., Guo, L., Fang, S., Wang, Y., & Xing, R. (2017). Androgen Receptor Regulates the Growth of Neuroblastoma Cells in vitro and in vivo. Frontiers in Neuroscience, 11, 116. http://doi.org/10.3389/fnins.2017.00116	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339338/		
ESR1	Lovén, J., Zinin, N., Wahlström, T., Müller, I., Brodin, P., Fredlund, E., … Henriksson, M. (2010). MYCN-regulated microRNAs repress estrogen receptor-α (ESR1) expression and neuronal differentiation in human neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 107(4), 1553–1558. http://doi.org/10.1073/pnas.0913517107	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824410/		
ESR2	Ashton, K., Proietto, A., Otton, G., Symonds, I., Mcevoy, M., Attia, J., . . . Scott, R. (2009). Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG: An International Journal of Obstetrics & Gynaecology, 116(8), 1053-1061. doi:10.1111/j.1471-0528.2009.02185.x	https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/j.1471-0528.2009.02185.x		
GnRHR	Cheng, C. K., Chow, B. K., & Leung, P. C. (2003). An Activator Protein 1-Like Motif Mediates 17β-Estradiol Repression of Gonadotropin-Releasing Hormone Receptor Promoter via an Estrogen Receptor α-Dependent Mechanism in Ovarian and Breast Cancer Cells. Molecular Endocrinology, 17(12), 2613-2629. doi:10.1210/me.2003-0217	https://academic.oup.com/mend/article-pdf/17/12/2613/10716982/mend2613.pdf		
VEGF	Glade Bender, J., Yamashiro, D. J., & Fox, E. (2011). Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors. The Oncologist, 16(11), 1614–1625. http://doi.org/10.1634/theoncologist.2011-0148	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233297/		
VEGFR	Kieran, M. W., Kalluri, R., & Cho, Y.-J. (2012). The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward. Cold Spring Harbor Perspectives in Medicine, 2(12), a006593. http://doi.org/10.1101/cshperspect.a006593	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543071/		